+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Incyte

  • ID: 5357329
  • Company Profile
  • January 2021
  • 56 pages
  • Datamonitor Healthcare
  • Incyte Corporation
The publisher explores Incyte’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Incyte continues to be driven by robust Jakafi sales.
  • Key themes - [1] Incyte continues to grow Jakafi volumes at a strong pace, with supplemental approvals and label expansions adding to the lifecycle management of the drug [2] Jakafi patent expiration in 2028 is a key event for Incyte as the drug will comprise a significant proportion of company revenues [3] Royalties and collaboration revenues will substantially bolster Incyte over the forecast period.
Model updates (6 November 2020)
  • Pemazyre forecast adjusted higher due to launch trend.
Model updates (4 August 2020)
  • Tafasitamab name changed to Monjuvi following US July approval
  • Itacitinib forecast pushed back due to treatment-naïve acute GVHD trial results
  • Jakafi forecast adjusted lower due to COVID-19 impact
  • Pemazyre 5EU and RoW forecast added due to pending EU approval decision.
Model updates (5 May 2020)
  • Jakafi forecast adjusted higher due to continued uptake in GVHD
  • Pemigatinib name changed to Pemazyre; forecast pulled forward due to earlier-than-anticipated approval for cholangiocarcinoma
  • Tafasitamab forecast added due to closing of licensing agreement with MorphoSys.
Model updates (13 February 2020)
  • Jakafi forecast adjusted higher due to continued growth in MF, strong growth in PV, and an above-expectations launch in steroid-refractory acute GVHD.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll